Thymalin polypeptide complex
Evidence Grade C — Moderate human evidence. 234 published studies, 156 human. 0 registered clinical trials.
Thymalin is an undefined mixture of peptides extracted from bovine (cow) thymus glands, developed in the Soviet Union in the 1970s. Unlike most compounds in this database, it is not a single defined molecule but a crude biological extract. It has been used clinically in Russia for immune restoration but has never been evaluated by Western regulatory agencies.
234 published studies: 156 human, 76 animal, 19 in-vitro, 5 reviews
Thymalin is approved in Russia for immune restoration indications. It has not been approved by the FDA, EMA, or other major Western regulatory agencies. A study of elderly subjects observed over 6–8 years reported mortality differences between treated and control groups, but this study's methodology has not been evaluated through Western regulatory review.
As an undefined biological mixture derived from animal tissue, Thymalin faces inherent challenges in molecular characterisation, batch-to-batch consistency, and quality standardisation. The clinical evidence base has not met the standards required for FDA or EMA approval.
Research suggests Thymalin may influence T-cell differentiation and immune cell function. As an undefined mixture of bovine thymus-derived peptides, the active component(s) and their specific molecular targets cannot be precisely characterised. The proposed mechanisms are based on immunological assessments from Russian clinical studies.
Research from the Khavinson group reports reduced mortality with combined Thymalin and Epithalamin treatment in elderly subjects followed for 6-8 years. However, nearly all clinical data originates from a single research group, sample sizes are very small (20-24 per group), and no confidence intervals were reported. As an undefined bovine tissue extract, Thymalin faces inherent challenges in batch-to-batch consistency and quality standardisation. A theoretical prion contamination risk exists for animal-derived brain and gland tissue products. Much of the supporting literature is in Russian only. Over 40 years of use in Russia is reportedly safe, but formal pharmacovigilance by Western standards is absent.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
